A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

NCT02908685 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

231

Enrollment

INDUSTRY

Sponsor class

Conditions

Muscular Atrophy, Spinal

Interventions

DRUG: Placebo
DRUG: Risdiplam

Sponsor

Hoffmann-La Roche